AMPK and mTOR in cellular energy homeostasis and drug targets.
By K. Inoki, Joungmok Kim, K. Guan. Annual Review of Pharmacology and Toxicology, 2012
780 citations recorded by the source corpus.
Subfields: Molecular Biology
View Paper: https://www.semanticscholar.org/paper/4d1d78e5173fc444e256c3dd74e41de5308c9b5e
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Molecular Biology
- Guido Kroemer
- Beth Levine
- L. Galluzzi
- Douglas R. Green
- Seamus J. Martin
- D. Rubinsztein
- Eric H. Baehrecke
- F. Pietrocola
Citations in the corpus
- The Neurology of mTOR (2014, positive): “in which the AMP/ATP ratio is high results in increased AMPK activity and suppression of mTOR-mediated growth pathways (Inoki et al., 2012).”
- Metabolic control of cell death (2014, background): “The AMPK-TORC1 checkpoint The target of rapamycin complex 1 (TORC1) is a major regulatory node that controls cell growth, proliferation, and autophagy through the kinase activity of mammalian target of rapamycin (mTOR).”
- Fasting, circadian rhythms, and time restricted feeding in healthy lifespan (2016, background): “The mTOR and AMPK pathways also modulate activities of downstream proteins, including the transcription regulators CREB, PPAR, FOXO, Hsf1, HNF, and PGC1 (Inoki et al., 2012).”
- Autophagy in malignant transformation and cancer progression (2015, positive): “Besides inhibiting the catalytic activity of MTORCI, AMPK directly stimulates autophagy by phosphorylating ULK1 as well as phosphatidylinositol 3-kinase, catalytic subunit type 3 (PIK3C3, best known as VPS34) and Beclin 1 (BECN1, the mammalian ortholog of yeast Atg6), two components of a multiprotei”
- Time restricted feeding without reducing caloric intake prevents metabolic diseases in mice fed a high fat diet (2012, positive): “Temporal Feeding Pattern Shapes Rhythms in CREB, mTOR, and AMPK Activities and in the Circadian Oscillator A HFD fed under an ad lib regimen perturbs metabolic regulators, including CREB, mTOR, and AMPK, and contributes to metabolic diseases (Altarejos and Montminy, 2011; Inoki et al., 2011).”